Different regions of the brain and spinal cord house different, specialized cells. Neuralstem’s technology enables the isolation and expansion of human neural stem cells from each of these regions of the developing central nervous system (CNS) in virtually unlimited numbers from a single donated tissue. More

Neuralstem’s technology uniquely enables the creation of stable neural stem cell lines from the human hippocampus, a part of the brain involved in memory and the generation of new neurons. From these cell lines, the company can create practically unlimited amounts of hippocampal neural stem cells. More

    • Neuralstem Appoints Richard Daly President and CEO 2.16.16

      Mr. Daly's commercial pharmaceutical leadership encompasses over 25 years of strategy, sales, marketing and operations experience. Richard Garr continues to serve Neuralstem as a director. More

    • Dr. Karl Johe Presents Cell Therapy Update 1.27.16

      Preliminary cSCI and stroke Phase I data presented at Phacilitate Cell & Gene Therapy World conference, with collective trial data analysis showing NSI-566 consistently demonstrated biological activity of motor improvement in all three ongoing cell therapy trial indications. More

    • Preclinical Alzheimer’s Disease Data Published 1.11.16

      Researchers concluded Neuralstem’s novel neuroprotective cortical cells engineered to express insulin-like growth factor-1 should be further studied as a possible disease-modifying Alzheimer’s intervention, in Stem Cells Translational MedicineMore

    • Novel Neurogenic NSI-189 MDD Ib
      Early Efficacy Data Published in Molecular Psychiatry 12.8.15

      Report cites Neuralstem’s first-in-class lead oral, small molecule safe and well-tolerated in major depressive disorder, with medium to large clinical effect size for all measures, with positive effects persisting after patients stopped receiving the drug. More

    • Neuralstem Clinical Trials Advancing 11.9.15

      Business update includes NSI-189/MDD Phase II protocol filed with the FDA and patient enrollment expected 1Q2016, and NSI-566/cSCI positive Phase I safety data presented in Oct. More

    • Dr. Eva Feldman presents NSI-566/ALS Phase I/II Data at ANA Annual Meeting 9.29.15

      Nine-month Phase II and combined Phase I/II NSI-566 ALS data was safe and well-tolerated; no acceleration of disease progression, and forced vital capacity (FVC) preservation correlated most strongly with ALSFRSr scoresMore

    • US District Court Rules In Favor Of Neuralstem In Patent Infringement Case 7.23.15

      Neuralstem, Inc. announced that the U.S. District Court for the District of Maryland dismissed StemCells, Inc.'s patent infringement case with prejudice in StemCells, Inc. v. Neuralstem, Inc. in favor of Neuralstem, on July 22, 2015. More

    • Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 6.29.15

      Trading on the NASDAQ Capital Market is expected to commence on July 13, 2015 under the symbol "CUR." More

    • HK532-IGF-1 Alzheimer's Disease Cell Therapy Poster At ISSCR Annual Meeting 6.26.15

      Neuralstem's HK532-IGF-1 cells enhanced learning cognition and memory consolidation in animal data presented by University of Michigan researchers, who also reported beta-amyloid plaque reduction in the cortex and hippocampus. More

    • Jonathan Lloyd Jones Appointed CFO 5.6.15

      Former CFO and/or VP of three biotech/ pharma companies and former Senior Director, Corporate Development, for Genzyme brings expertise in corporate finance, licensing, and partnering. More

    • NSI-566 ALS Phase II Topline Results Announced 3.12.15

      Cervical intervention deemed safe, 16 million cells maximum tolerated dose established, and secondary efficacy endpoints reviewed. More

          • NSI-189/MDD Neurogenic Biomarker Data Presented 11.17.14

            Depression blood-based biomarker analysis presented at CNS Summit shows NSI-189 rapidly and persistently efficacious. More